Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $1.3 million.

  • Vistagen Therapeutics' Accounts Payables rose 2319.54% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year increase of 2319.54%. This contributed to the annual value of $653000.0 for FY2025, which is 5778.93% down from last year.
  • Latest data reveals that Vistagen Therapeutics reported Accounts Payables of $1.3 million as of Q4 2025, which was up 2319.54% from $1.8 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Accounts Payables peaked at $5.5 million during Q2 2022, and registered a low of $486000.0 during Q2 2025.
  • Its 5-year average for Accounts Payables is $1.8 million, with a median of $1.6 million in 2022.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 1534133.33% in 2021, then crashed by 7034.17% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Accounts Payables (Quarter) stood at $1.9 million in 2021, then dropped by 17.96% to $1.6 million in 2022, then increased by 8.64% to $1.7 million in 2023, then crashed by 40.18% to $1.0 million in 2024, then increased by 23.2% to $1.3 million in 2025.
  • Its Accounts Payables was $1.3 million in Q4 2025, compared to $1.8 million in Q3 2025 and $486000.0 in Q2 2025.